Biotherapeutics News and Research

RSS

New drug shows promise for epilepsy patients with resistant seizures

In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

9 Oct 2023

Could baseline gut microbiota predict the immune responses elicited by COVID-19 vaccines?

Researchers characterized the gut microbiota composition associated with the durability of COVID-19 vaccine-induced immunity.

27 Sep 2023

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC).

From Cell Signaling Technology 20 Sep 2023

Big Tuna and automated buffer exchange: An interview with Unchained Labs

In this interview, AZoNetwork speaks with Joe Barco, the Senior Director of Workflow Marketing at Unchained Labs, about the benefits of automated buffer exchange with Big Tuna.

From Unchained Labs 4 Sep 2023

Study shows that CD98hc can be targeted to deliver biotherapeutics in brain

Researchers engineered and characterized a blood-brain barrier transport vehicle targeting the CD98 heavy chain of heterodimeric amino acid transporters.

24 Aug 2023

Study finds way to reverse gene silencing in inner ear cells

A deafened adult cannot recover the ability to hear, because the sensory hearing cells of the inner ear don't regenerate after damage.

14 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

Fecal transplants safe and effective in treating advanced melanoma, clinical trial shows

In a world-first clinical trial published in the journal Nature Medicine, a multi-center study from Lawson Health Research Institute, the Centre hospitalier de l'Université de Montréal and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

7 Jul 2023

Study finds the risk of recurrence of active disease in older patients with MS after discontinuing therapy

An article published today in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.

23 Jun 2023

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.

22 May 2023

Novel gene-editing strategy harnesses an unusual protective ability to eliminate HIV-1 infection

Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses.

19 May 2023

LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark

Through a recent platform demonstration project, LabGenius’ machine learning-driven lead optimisation capability delivered dozens of novel T-cell engagers with best-in-class killing selectivity.

From LabGenius 16 May 2023

MHRA research evaluates two different approaches to cancer therapies

The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.

13 Apr 2023

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses.

From FUJIFILM Irvine Scientific 11 Apr 2023

Snapping at new biotech breakthroughs with Gator Pro

In this interview, we speak to Subodh Nimkar, Marketing Director at Gator Bio, about their latest technology, Gator Pro which allows for fast, reliable, and high-quality data.

From Gator Bio, Inc. 21 Mar 2023

Realizing the Importance of Medical Electronic Devices

News Medical speaks to Brian Anthony, co-director of MIT’s Medical Electronic Device Realization Center, about the effect machine learning and sensor technologies have had on medical device engineering, as well as the Bioprocess Data Analytics and Machine Learning course he co-leads at MIT.

From Massachusetts Institute of Technology (MIT) 20 Mar 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

InDevR raises $9 million in series B financing and partners with bioMérieux

New partnerships will drive the commercial expansion of InDevR’s game-changing solutions for vaccines and biotherapeutics.

20 Jan 2023

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Researchers have designed the first 'living medicine' to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.

19 Jan 2023

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

From Vector BioPharma 10 Jan 2023